The pharmacokinetics of imipenem (thienamycin-formamidine) and the renal dehydropeptidase inhibitor cilastatin sodium in normal subjects and patients with renal failure.
about
Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients.Pharmacokinetics of imipenem-cilastatin in critically ill patients undergoing continuous venovenous hemofiltration.Single dose pharmacokinetics of lamivudine in subjects with impaired renal function and the effect of haemodialysis.Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease.Removal of imipenem and cilastatin by hemodialysis in patients with end-stage renal failurePooled population pharmacokinetic model of imipenem in plasma and the lung epithelial lining fluidClinical review: Drug metabolism and nonrenal clearance in acute kidney injury.Pharmacokinetics and dosage adjustment in patients with renal dysfunction.Treatment of gram-negative infections in patients with renal impairment: new alternatives to aminoglycosides.Use of Monte Carlo Simulations to Determine Optimal Carbapenem Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy.Suboptimal antimicrobial drug exposure in patients with renal impairment.Pharmacokinetics of imipenem and cilastatin after their simultaneous administration to the elderly.Comparative activities of telavancin combined with nafcillin, imipenem, and gentamicin against Staphylococcus aureusElevated plasma cysteinylglycine levels caused by cilastatin-associated antibiotic treatment.
P2860
Q33836550-5BF30DFF-70D7-4552-8C4E-077C82FDF584Q35139365-4371CF25-5314-4959-8B84-9FCFE536268DQ35803067-346A9F2A-256C-4074-8B02-1749163DAEB9Q35808464-22E678D2-A1E3-4995-9C35-39DBDB8A6CBFQ36754535-9EF8DB7A-6CC3-4878-A918-06284A59840CQ36924714-42AADB7D-ED26-4232-B23F-EABEE7C41AD7Q37336958-D23D1386-2E46-413C-B4E1-8920A799ED1FQ37526589-6BEAE1EA-9A9C-463A-BC45-455D3E527E02Q39558431-BC03B6B0-366F-4829-A205-34F98FF05CE6Q39965478-36FD9741-9FF8-40B8-8368-56844859A4E8Q40897031-10F4DC6B-082B-4BF7-AA63-151A653DEFD2Q41884287-C3DC1524-606A-4844-B80A-7A920BCD2342Q42090736-04D26C65-79A8-4903-B155-A477713A3896Q46447872-659DF7F3-B97A-4C3C-9C9D-CE0A0137EFC4
P2860
The pharmacokinetics of imipenem (thienamycin-formamidine) and the renal dehydropeptidase inhibitor cilastatin sodium in normal subjects and patients with renal failure.
description
1984 nî lūn-bûn
@nan
1984 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1984 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1984年の論文
@ja
1984年論文
@yue
1984年論文
@zh-hant
1984年論文
@zh-hk
1984年論文
@zh-mo
1984年論文
@zh-tw
1984年论文
@wuu
name
The pharmacokinetics of imipen ...... d patients with renal failure.
@ast
The pharmacokinetics of imipen ...... d patients with renal failure.
@en
The pharmacokinetics of imipenem
@nl
type
label
The pharmacokinetics of imipen ...... d patients with renal failure.
@ast
The pharmacokinetics of imipen ...... d patients with renal failure.
@en
The pharmacokinetics of imipenem
@nl
prefLabel
The pharmacokinetics of imipen ...... d patients with renal failure.
@ast
The pharmacokinetics of imipen ...... d patients with renal failure.
@en
The pharmacokinetics of imipenem
@nl
P2093
P2860
P1476
The pharmacokinetics of imipen ...... d patients with renal failure.
@en
P2093
Buntinx AP
De Broe ME
Entwistle LA
Verpooten GA
P2860
P304
P356
10.1111/J.1365-2125.1984.TB02451.X
P407
P577
1984-08-01T00:00:00Z